The UK and US have reached a major commercial pact that will maintain zero tariffs on UK drug products going into the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to boost spending on drugs through the public health system. This move guarantees that import taxes on these key goods will be held at nothing for a duration of three years.
This deal is in response to recent warnings to hike tariffs on patented drug products, with figures discussed reaching one hundred percent.
"This arrangement with the UK strengthens the worldwide climate for new treatments and establishes much-needed equity to American-British pharmaceutical trade," an announcement said.
Commercial Significance
Pharmaceuticals constitute one of the UK's largest goods shipped to the US, which is clearly the primary buyer for large British pharmaceutical firms.
Export figures show that in the 12 months leading up to last September, the UK exported drugs totaling billions to the US. This value accounted for nearly one-fifth of total UK exports in that period.
"This deal protects jobs, increases capital expenditure and paves the way for the UK to become a international leader for medical research," the Business and Trade Secretary commented.
Specific UK Commitments
The agreement includes several key changes from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it judges new treatments to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a goal to increase total NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must return to the NHS to prevent overspending will be restricted at fifteen percent. In the past, refunds topped 20%.
Industry Background
This agreement follows a protracted row between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
This friction were intensified by claims that American patients were paying several times more for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar investments have been directed toward projects in the United States.
One official acknowledged that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had decreased as a percentage of its total funding over the past decade.
